Neoalbaconol induces energy depletion and multiple cell death in cancer cells by targeting PDK1-PI3-K/Akt signaling pathway.
Many natural compounds derived from plants or microbes show promising potential for anticancer treatment, but few have been found to target energy-relevant regulators. In this study, we report that neoalbaconol (NA), a novel small-molecular compound isolated from the fungus, Albatrellus confluens, could target 3-phosphoinositide-dependent protein kinase 1 (PDK1) and inhibit its downstream phosphoinositide-3 kinase (PI3-K)/Akt-hexokinase 2 (HK2) pathway, which eventually resulted in energy depletion. By targeting PDK1, NA reduced the consumption of glucose and ATP generation, activated autophagy and caused apoptotic and necroptotic death of cancer cells through independent pathway. Necroptosis was remarkably induced, which was confirmed by several necroptosis-specific markers: the activation of autophagy, presence of necrotic morphology, increase of receptor-interacting protein 1 (RIP1)/RIP3 colocalization and interaction and rescued by necroptosis inhibitor necrostatin-1. The possibility that Akt overexpression reversed the NA-induced energy crisis confirmed the importance of the PDK1-Akt-energy pathway in NA-mediated cell death. Moreover, NA shows the capability to inhibit PI3-K/Akt signaling and suppress tumor growth in the nasopharyngeal carcinoma (NPC) nude mouse model. These results supported the feasibility of NA in anticancer treatments.
1] Xiangya School of Medicine, Cancer Research Institute, Central South University, Hunan, China [2] Key Laboratory of Chinese Ministry of Education, Central South University, Hunan, China [3] Key Laboratory of Carcinogenesis of Chinese Ministry of Public Health, Central South University, Hunan, China.
Q
Q
Deng
X
X
Yu
L
L
Xiao
Z
Z
Hu
X
X
Luo
Y
Y
Tao
L
L
Yang
X
X
Liu
H
H
Chen
Z
Z
Ding
T
T
Feng
Y
Y
Tang
X
X
Weng
J
J
Gao
W
W
Yi
A M
AM
Bode
Z
Z
Dong
J
J
Liu
Y
Y
Cao
D064413:3-Phosphoinositide-Dependent Protein Kinases / Q000378:metabolism*; D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D001343:Autophagy / Q000187:drug effects; D002277:Carcinoma; D016923:Cell Death / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004195:Disease Models, Animal; D015536:Down-Regulation / Q000187:drug effects; D004354:Drug Screening Assays, Antitumor; D004734:Energy Metabolism / Q000187:drug effects*; D005947:Glucose / Q000378:metabolism; D006593:Hexokinase / Q000378:metabolism; D051379:Mice; D008819:Mice, Nude; D008954:Models, Biological; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000473:pathology; D009336:Necrosis; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*; D012717:Sesquiterpenes / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects; D013379:Substrate Specificity / Q000187:drug effects; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D012717:Sesquiterpenes; C586893:neoalbaconol; D000255:Adenosine Triphosphate; D019869:Phosphatidylinositol 3-Kinases; D006593:Hexokinase; D064413:3-Phosphoinositide-Dependent Protein Kinases; D051057:Proto-Oncogene Proteins c-akt; D005947:Glucose